MCID: SGN002
MIFTS: 45

Signet Ring Cell Adenocarcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Signet Ring Cell Adenocarcinoma

Aliases & Descriptions for Signet Ring Cell Adenocarcinoma:

Name: Signet Ring Cell Adenocarcinoma 12 14
Carcinoma, Signet Ring Cell 42 69
Signet Ring Cell Carcinoma 12
Carcinoma Signet Ring Cell 52
Signet Ring Carcinoma Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3493
MeSH 42 D018279
NCIt 47 C3774
UMLS 69 C0206696

Summaries for Signet Ring Cell Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which have signet ring appearance.

MalaCards based summary : Signet Ring Cell Adenocarcinoma, also known as carcinoma, signet ring cell, is related to gallbladder signet ring cell adenocarcinoma and linitis plastica. An important gene associated with Signet Ring Cell Adenocarcinoma is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Development HGF signaling pathway and Cytoskeletal Signaling. The drugs Irinotecan and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include prostate, colon and lung, and related phenotypes are cardiovascular system and cellular

Related Diseases for Signet Ring Cell Adenocarcinoma

Diseases related to Signet Ring Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
id Related Disease Score Top Affiliating Genes
1 gallbladder signet ring cell adenocarcinoma 31.1 CDH1 CDX2 CHGA CTNNB1 KRT20 KRT7
2 linitis plastica 30.4 CDH1 TP53
3 gastric signet ring cell adenocarcinoma 12.4
4 bile duct signet ring cell carcinoma 12.3
5 bladder signet ring cell adenocarcinoma 12.2
6 breast signet ring cell adenocarcinoma 12.2
7 prostate signet ring cell adenocarcinoma 12.2
8 pancreatic signet ring cell adenocarcinoma 12.1
9 ampullary signet ring cell adenocarcinoma 12.1
10 diffuse gastric cancer 11.9
11 gastric cancer risk after h. pylori infection 11.2
12 rectum signet ring adenocarcinoma 11.1
13 adenocarcinoma 10.8
14 gastritis 10.3 CDH1 KRT20
15 ascending colon cancer 10.3 KRT20 MUC2
16 choroid epithelioid cell melanoma 10.3 CDX2 MUC2
17 radiculopathy 10.3 KRT20 KRT7
18 bronchus mucoepidermoid carcinoma 10.3 KRT20 KRT7
19 steroid-induced glaucoma - borderline 10.3 KRT20 KRT7
20 infiltrative basal cell carcinoma 10.3 CDH1 KRT20
21 nonossifying fibromyxoid tumor 10.3 KRT20 KRT7
22 agenesis and aplasia of uterine body 10.3 KRT20 KRT7
23 extramedullary plasmacytoma 10.3 CDX2 KRT20
24 synovitis 10.3 CDX2 KRT7
25 prostatitis 10.2
26 uterine ligament mucinous adenocarcinoma 10.2 CDX2 KRT7
27 ovarian squamous cell carcinoma 10.2 CDH1 KRT20 MUC6
28 waterhouse-friderichsen syndrome 10.2 KRT20 KRT7
29 bronchitis 10.2 CDH1 TP53
30 familial renal oncocytoma 10.2 CDH1 KRT20
31 cervix endometriosis 10.2 CDX2 KRT20 MUC2
32 ureter adenocarcinoma 10.2 CDX2 MUC2
33 acute eustachian salpingitis 10.2 CDH1 CDX2 MUC2
34 small intestine leiomyoma 10.2 KRT20 TP53
35 myotonic disease 10.2 CDH1 KRT20 KRT7
36 clear cell hidradenoma 10.2 KRT20 TP53
37 motor neuron disease 10.2 MUC1 MUC6
38 spiradenoma 10.2 KRT20 TP53
39 tanycytic ependymoma 10.2 CDH1 MUC1
40 lateral sinus thrombosis 10.2 CDX2 MUC2 MUC6
41 apocrine adenocarcinoma 10.2 CDX2 KRT20 KRT7
42 mucosal melanoma 10.2 CDX2 KRT20 KRT7
43 myotonia congenita 10.2 CDX2 KRT20 KRT7
44 prolactin producing pituitary tumor 10.2 CHGA MUC1
45 peripheral nervous system ganglioneuroblastoma 10.2 CDX2 KRT7
46 ariboflavinosis 10.2 CDX2 KRT20 KRT7
47 non specific chronic endometritis 10.2 CHGA KRT20 KRT7
48 spasmodic dysphonia 10.2 CHGA KRT20 KRT7
49 trombiculiasis 10.2 CHGA MUC1
50 bile duct clear cell adenocarcinoma 10.1 SRC TP53

Graphical network of the top 20 diseases related to Signet Ring Cell Adenocarcinoma:



Diseases related to Signet Ring Cell Adenocarcinoma

Symptoms & Phenotypes for Signet Ring Cell Adenocarcinoma

MGI Mouse Phenotypes related to Signet Ring Cell Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.87 CDH1 CDX2 CHGA CTNNB1 MUC2 TP53
2 cellular MP:0005384 9.86 CDH1 CDX2 CTNNB1 KRT7 MUC2 SRC
3 endocrine/exocrine gland MP:0005379 9.76 TP53 TUB CDH1 CDX2 CHGA CTNNB1
4 neoplasm MP:0002006 9.43 CDH1 CDX2 CTNNB1 MUC2 SRC TP53
5 pigmentation MP:0001186 8.92 CTNNB1 SRC TP53 TUB

Drugs & Therapeutics for Signet Ring Cell Adenocarcinoma

Drugs for Signet Ring Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
2
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
3
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
4
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
5
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
6
Pancrelipase Approved Phase 3,Phase 1 53608-75-6
7
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
9
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
10
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
11 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
12 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
14 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
15 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
17 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
18 Antidotes Phase 3,Phase 2,Phase 1
19 Antimetabolites Phase 3,Phase 2,Phase 1
20 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
21 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
22 Calcium, Dietary Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Micronutrients Phase 3,Phase 2,Phase 1
25 Protective Agents Phase 3,Phase 2,Phase 1
26 Trace Elements Phase 3,Phase 2,Phase 1
27 Vitamin B Complex Phase 3,Phase 2,Phase 1
28 Vitamins Phase 3,Phase 2,Phase 1
29 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
30 Mitomycins Phase 3,Phase 1,Phase 2
31 pancreatin Phase 3,Phase 1
32 Pharmaceutical Solutions Phase 3
33 Endothelial Growth Factors Phase 3,Phase 2
34 Hematinics Phase 3
35 Immunoglobulin G Phase 3
36 Mitogens Phase 3,Phase 2
37 Cola Nutraceutical Phase 3,Phase 2,Phase 1
38 Folate Nutraceutical Phase 3,Phase 2,Phase 1
39 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
40
Cetuximab Approved Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
41
Ramucirumab Approved, Investigational Phase 2 947687-13-0
42
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
43
nivolumab Approved Phase 2 946414-94-4
44
Indomethacin Approved, Investigational Phase 1, Phase 2 53-86-1 3715
45
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
46 Alkylating Agents Phase 1, Phase 2
47 Anti-Bacterial Agents Phase 1, Phase 2
48 Antibiotics, Antitubercular Phase 1, Phase 2
49 Nucleic Acid Synthesis Inhibitors Phase 1, Phase 2
50 Protein Kinase Inhibitors Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show all 34)
id Name Status NCT ID Phase
1 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3
2 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
3 Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis Recruiting NCT02179489 Phase 3
4 Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients Recruiting NCT01226394 Phase 3
5 D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma Recruiting NCT01882933 Phase 3
6 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3
7 Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery Terminated NCT00068692 Phase 3
8 Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Unknown status NCT01079780 Phase 2
9 Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients Completed NCT02575859 Phase 1, Phase 2
10 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2
11 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Recruiting NCT01814501 Phase 2
12 Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer Recruiting NCT01871571 Phase 2
13 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting NCT01802320 Phase 2
14 Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer Active, not recruiting NCT01652196 Phase 2
15 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Not yet recruiting NCT02978625 Phase 2
16 Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer Terminated NCT00002796 Phase 1, Phase 2
17 Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer Terminated NCT00052585 Phase 2
18 Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer Terminated NCT01285102 Phase 2
19 Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Withdrawn NCT02235324 Phase 2
20 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
21 A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer Completed NCT00060411 Phase 1
22 Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer Completed NCT00003799 Phase 1
23 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Recruiting NCT01643499 Phase 1
24 CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery Recruiting NCT02232152 Phase 1
25 Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver Recruiting NCT02110953 Phase 1
26 Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer Active, not recruiting NCT01923337 Phase 1
27 Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer Active, not recruiting NCT02270606 Phase 1
28 Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer Terminated NCT01198535 Phase 1
29 Prognosis of Signet Ring Cells in Upper Digestive Neoplasms Completed NCT01249859
30 Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma Completed NCT01824966
31 NBI for Identifying Resection Margin Status in Gastric Cancer Completed NCT02926716
32 Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care Completed NCT01726296
33 Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma Recruiting NCT01717924
34 Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery Terminated NCT00835679 Early Phase 1

Search NIH Clinical Center for Signet Ring Cell Adenocarcinoma

Cochrane evidence based reviews: carcinoma, signet ring cell

Genetic Tests for Signet Ring Cell Adenocarcinoma

Anatomical Context for Signet Ring Cell Adenocarcinoma

MalaCards organs/tissues related to Signet Ring Cell Adenocarcinoma:

39
Prostate, Colon, Lung, Bone, Bone Marrow, Cervix, Skin

Publications for Signet Ring Cell Adenocarcinoma

Articles related to Signet Ring Cell Adenocarcinoma:

(show top 50) (show all 69)
id Title Authors Year
1
Pulmonary Signet-Ring Cell Adenocarcinoma Metastatic to the Skin. ( 27898475 )
2016
2
Primary signet ring cell adenocarcinoma of the uterine cervix - A rare neoplasm that raises the question of metastasis to the cervix. ( 27331127 )
2016
3
A rare case of metastatic germ cell tumor to stomach and duodenum masquerading as signet ring cell adenocarcinoma. ( 27668229 )
2016
4
Primary signet-ring cell adenocarcinoma of the head and neck: a case study and brief review. ( 27185232 )
2016
5
A Rare Case of an Adult with Untreated Bladder Exstrophy Presenting with Signet-Ring Cell Adenocarcinoma of Urinary Bladder. ( 28050437 )
2016
6
Colonic-type appendiceal adenocarcinoma: an intermediate prognosis between mucinous and signet ring cell adenocarcinoma. ( 26735622 )
2015
7
Signet Ring Cell Adenocarcinoma and Bilateral Leptomeningeal Involvement of Optic Nerve Sheaths. ( 25839780 )
2015
8
Bone marrow infiltration as the initial presentation of gastric signet ring cell adenocarcinoma. ( 25436133 )
2014
9
A case with primary signet ring cell adenocarcinoma of the prostate and review of the literature. ( 25017602 )
2014
10
The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma. ( 24200394 )
2014
11
Biopsy-triggered gastric signet ring cell adenocarcinoma proliferation. ( 25524189 )
2014
12
Primary Signet Ring Cell Adenocarcinoma of the Urinary Bladder: A Report of 2 Cases. ( 26955554 )
2014
13
Primary signet-ring cell adenocarcinoma of the uterine cervix: case report and review of the literature. ( 24020147 )
2013
14
Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: results of a multicentre retrospective study. ( 23313257 )
2013
15
Signet-ring cell adenocarcinoma of rectum with breast metastases diagnosed on FNA cytology: case report and literature review. ( 22429319 )
2013
16
Primary pure signet-ring cell adenocarcinoma of the urinary bladder: a report of three cases with an immunohistochemical study. ( 22120516 )
2012
17
Metastatic signet ring cell adenocarcinoma of the bladder: responsive to treatment? ( 22396377 )
2012
18
Signet ring cell adenocarcinoma of the ampulla of Vater: a rare patho. ( 23130863 )
2012
19
Secondary signet-ring cell adenocarcinoma of urinary bladder from a gastric primary. ( 21747602 )
2011
20
A case of signet ring cell adenocarcinoma of the bladder with spontaneous urinary extravasation. ( 22022068 )
2011
21
Primary pure signet ring cell adenocarcinoma of non-Barrett's esophagus. ( 22275019 )
2011
22
An unusual case of signet ring cell adenocarcinoma of the prostate. ( 21797141 )
2011
23
The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. ( 22005144 )
2011
24
Interval signet-ring cell adenocarcinoma of the colon: missed or de novo? ( 21540911 )
2011
25
Morphometric distinction of signet-ring cell adenocarcinoma cells from foamy macrophages in gastric endoscopic biopsies. ( 22102070 )
2011
26
Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report. ( 21719143 )
2011
27
Tonsillar metastasis of signet-ring cell adenocarcinoma of the colon. ( 20737376 )
2010
28
Primary signet-ring cell adenocarcinoma of the endometrium: case report and review of the literature. ( 20407328 )
2010
29
Signet-ring cell adenocarcinoma of the bladder: case series between 1990-2009. ( 20378938 )
2010
30
Sister Mary Joseph's nodule as the sole presenting sign of gastric signet ring cell adenocarcinoma. ( 20739130 )
2010
31
Unfound gastric signet ring-cell adenocarcinoma after gastric biopsy. ( 20425670 )
2010
32
Signet ring cell adenocarcinoma of the oropharynx: presentation of a rare case and review of the literature. ( 19446973 )
2009
33
Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. ( 18789486 )
2009
34
Signet-ring-cell adenocarcinoma of the myocardium presenting as persistent pleural effusions. ( 19772035 )
2009
35
Gastric signet-ring cell adenocarcinoma presenting with left arm deep-vein thrombosis and bilateral chylothorax. ( 18263634 )
2008
36
Metastatic signet ring cell adenocarcinoma of bone marrow with bilateral ovarian masses: a case report. ( 19019234 )
2008
37
Signet-ring cell adenocarcinoma of sinonasal tract: an immunohistochemical study of the mucins profile. ( 17550327 )
2007
38
Synchronous gastric gastrointestinal stromal tumor and signet-ring cell adenocarcinoma: a case report. ( 17913950 )
2007
39
Gastric signet-ring cell adenocarcinoma metastatic to the gingiva: a case report. ( 16831674 )
2006
40
FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. ( 15647683 )
2005
41
Primary signet ring cell adenocarcinoma of the bladder. ( 15951737 )
2005
42
Signet-ring-cell adenocarcinoma arising from a hyperplastic polyp in the stomach. ( 15758936 )
2005
43
Signet ring cell adenocarcinoma of the urachus. ( 15379946 )
2004
44
Epididymal metastasis from gastric signet ring cell adenocarcinoma. ( 12010596 )
2002
45
Primary signet ring cell adenocarcinomas of the lung: a clinicopathological study of 15 cases. ( 11683941 )
2001
46
Severe prognosis of signet-ring cell adenocarcinoma occurring in Meckel's diverticulum. ( 11300339 )
2001
47
Gastric signet ring cell adenocarcinoma metastatic to the iris. ( 11239875 )
2001
48
Colon signet ring cell adenocarcinoma: immunohistochemical characterization and comparison with gastric and typical colon adenocarcinomas. ( 10981869 )
2000
49
Neuroendocrine signet ring cell adenocarcinoma of the endocervix. ( 11240807 )
1999
50
Oliguria, an unusual presentation of primary signet ring-cell adenocarcinoma of the urinary bladder: a case report and review of the literature. ( 9989424 )
1999

Variations for Signet Ring Cell Adenocarcinoma

Expression for Signet Ring Cell Adenocarcinoma

Search GEO for disease gene expression data for Signet Ring Cell Adenocarcinoma.

Pathways for Signet Ring Cell Adenocarcinoma

Pathways related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 CDH1 CTNNB1 SRC TP53
2 12.29 CDH1 KRT20 KRT7 MUC1
3
Show member pathways
12.19 MUC1 MUC2 MUC6 SRC
4
Show member pathways
12.1 CDH1 CTNNB1 SRC
5
Show member pathways
12.06 CDH1 CTNNB1 SRC TP53
6
Show member pathways
12.05 CDH1 CTNNB1 MUC1 SRC TP53
7 11.98 CDH1 CTNNB1 TP53
8
Show member pathways
11.95 MUC1 MUC2 MUC6
9 11.92 CTNNB1 SRC TP53
10 11.89 CDH1 CTNNB1 SRC TP53
11 11.85 CDH1 CTNNB1 SRC
12 11.82 CTNNB1 SRC TP53
13 11.79 CTNNB1 SRC TP53
14 11.78 CDH1 CTNNB1 MUC1
15
Show member pathways
11.76 MUC1 MUC2 MUC6
16
Show member pathways
11.66 CDH1 CTNNB1 SRC
17 11.55 CDH1 CTNNB1 SRC
18 11.5 CDH1 SRC TP53
19 11.47 CDH1 CTNNB1 SRC
20 11.16 CDH1 CTNNB1 SRC
21 11.1 CDH1 CTNNB1 SRC
22 10.95 CDH1 CTNNB1 SRC
23 10.87 CDH1 SRC
24 10.65 CDH1 CTNNB1
25 10.59 CDH1 CTNNB1 TP53
26 10.2 CDH1 CTNNB1 SRC

GO Terms for Signet Ring Cell Adenocarcinoma

Cellular components related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 9.33 MUC1 MUC2 MUC6
2 apical junction complex GO:0043296 9.26 CDH1 CTNNB1
3 catenin complex GO:0016342 8.96 CDH1 CTNNB1
4 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.77 CDH1 CDX2 CTNNB1 SRC TP53
2 single organismal cell-cell adhesion GO:0016337 9.61 CDH1 CTNNB1 SRC
3 bone resorption GO:0045453 9.51 CTNNB1 SRC
4 O-glycan processing GO:0016266 9.5 MUC1 MUC2 MUC6
5 anterior/posterior axis specification GO:0009948 9.49 CDX2 CTNNB1
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.48 MUC1 TP53
7 negative regulation of telomerase activity GO:0051974 9.46 SRC TP53
8 maintenance of gastrointestinal epithelium GO:0030277 9.4 MUC2 MUC6
9 adherens junction organization GO:0034332 9.33 CDH1 CTNNB1 SRC
10 cellular response to indole-3-methanol GO:0071681 9.26 CDH1 CTNNB1
11 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.26 MUC1 MUC2 MUC6 SRC
12 entry of bacterium into host cell GO:0035635 8.8 CDH1 CTNNB1 SRC

Sources for Signet Ring Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....